News | PET Imaging | September 15, 2026

First FDA-cleared MR-guided PET enhancement software, with automated amyloid Centiloid and tau quantification.

MR-guided PET Enhancement Software Gets FDA Clearance

Photo: Getty Images


Sept. 15, 2026 — Microstructure Imaging, Inc. (MICSI) has received FDA 510(k) clearance for MICSI-PET, a neurological PET software platform combining MR-guided PET enhancement with automated amyloid and tau quantification.

The platform uses structural MRI to guide PET denoising and super-resolution, producing higher-quality PET images while maintaining quantitative PET information. The platform provides automated Centiloid quantification for amyloid PET and CenTauR quantification for tau PET, along with regional SUVr measurements and z-scores compared with normative controls.

FDA Approved

The platform supports amyloid, tau and FDG PET and was developed and validated for real-world deployment across PET and MRI systems from major vendors and multiple generations of scanner hardware.

“The difference can be dramatic in borderline amyloid cases,” said Lawrence N. Tanenbaum, MD, FACR, neuroradiologist and imaging technology advisor. “When you’re trying to determine whether there is true cortical sparing, MICSI-PET can make the pattern substantially easier to see. Adding automated quantification to that improved visualization gives the reader a much more powerful way to evaluate the examination.”

MICSI-PET integrates into existing clinical imaging workflows, adding MR-guided enhancement and automated quantification to existing positron emission tomography infrastructure.

Building on this clinical momentum, MICSI is anticipating a $2.275 million Phase II SBIR award from the National Cancer Institute to support multi-center clinical validation of its upcoming neuroimaging platform in collaboration with NYU Langone Health and Memorial Sloan Kettering Cancer Center.

 

MICSI PET FDA

 


Additional Content

News | Lung Imaging

Nov.2, 2026 – SimonMed has announced the clinical launch of two advanced lung imaging technologies, CT:VQ and LDAf, in ...

Time November 02, 2026
arrow
News | X-Ray

Oct. 28, 2026 — HOPPR has announced the beta release of the HOPPR FS MSK Whole-Body Narrative Model, a vision-language ...

Time October 28, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Women's Health

Oct. 15, 2026— SimBioSys has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight Risk, its ...

Time October 19, 2026
arrow
News | Molecular Imaging

Editor's Note: This article has been updated to correct an earlier version. Oct. 15, 2026 — GE HealthCare has announced ...

Time October 16, 2026
arrow
Subscribe Now